Summary
Global Markets Direct’s, ‘Ferring International Center S.A. - Product Pipeline Review - 2016’, provides an overview of the Ferring International Center S.A.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Ferring International Center S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Ferring International Center S.A.
- The report provides overview of Ferring International Center S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ferring International Center S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ferring International Center S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Ferring International Center S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ferring International Center S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ferring International Center S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Ferring International Center S.A. Snapshot 6
Ferring International Center S.A. Overview 6
Key Information 6
Key Facts 6
Ferring International Center S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
Ferring International Center S.A. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Ferring International Center S.A. - Pipeline Products Glance 15
Ferring International Center S.A. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Ferring International Center S.A. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Ferring International Center S.A. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Ferring International Center S.A. - Drug Profiles 19
follitropin delta 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Testavan 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
degarelix acetate 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
elobixibat 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
selepressin 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
barusiban 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
carbetocin 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
FE-999301 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
merotocin 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FE-201874 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
FE-204038 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
FE-999310 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule for Undisclosed Indication 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Ferring International Center S.A. - Pipeline Analysis 34
Ferring International Center S.A. - Pipeline Products by Target 34
Ferring International Center S.A. - Pipeline Products by Route of Administration 35
Ferring International Center S.A. - Pipeline Products by Molecule Type 36
Ferring International Center S.A. - Pipeline Products by Mechanism of Action 37
Ferring International Center S.A. - Recent Pipeline Updates 38
Ferring International Center S.A. - Dormant Projects 41
Ferring International Center S.A. - Discontinued Pipeline Products 42
Discontinued Pipeline Product Profiles 42
DR-2011 42
Ferring International Center S.A. - Locations and Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List of Tables
Ferring International Center S.A., Key Information 6
Ferring International Center S.A., Key Facts 6
Ferring International Center S.A. - Pipeline by Indication, 2016 8
Ferring International Center S.A. - Pipeline by Stage of Development, 2016 9
Ferring International Center S.A. - Monotherapy Products in Pipeline, 2016 10
Ferring International Center S.A. - Partnered Products in Pipeline, 2016 11
Ferring International Center S.A. - Partnered Products/ Combination Treatment Modalities, 2016 12
Ferring International Center S.A. - Out-Licensed Products in Pipeline, 2016 13
Ferring International Center S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
Ferring International Center S.A. - Pre-Registration, 2016 15
Ferring International Center S.A. - Phase III, 2016 16
Ferring International Center S.A. - Phase II, 2016 17
Ferring International Center S.A. - Preclinical, 2016 18
Ferring International Center S.A. - Pipeline by Target, 2016 34
Ferring International Center S.A. - Pipeline by Route of Administration, 2016 35
Ferring International Center S.A. - Pipeline by Molecule Type, 2016 36
Ferring International Center S.A. - Pipeline Products by Mechanism of Action, 2016 37
Ferring International Center S.A. - Recent Pipeline Updates, 2016 38
Ferring International Center S.A. - Dormant Developmental Projects,2016 41
Ferring International Center S.A. - Discontinued Pipeline Products, 2016 42
Ferring International Center S.A., Other Locations 43
Ferring International Center S.A., Subsidiaries 44
List of Figures
Ferring International Center S.A. - Pipeline by Top 10 Indication, 2016 8
Ferring International Center S.A. - Pipeline by Stage of Development, 2016 9
Ferring International Center S.A. - Monotherapy Products in Pipeline, 2016 10
Ferring International Center S.A. - Out-Licensed Products in Pipeline, 2016 13
Ferring International Center S.A. - Pipeline by Target, 2016 34
Ferring International Center S.A. - Pipeline by Route of Administration, 2016 35
Ferring International Center S.A. - Pipeline by Molecule Type, 2016 36
Ferring International Center S.A. - Pipeline Products by Mechanism of Action, 2016 37
